QuidelOrtho shares fell roughly 14% after third-quarter 2026 results showed China revenue down 45% and respiratory revenue down 39%. Levi & Korsinsky is investigating on behalf of investors who lost money.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Point-of-Care revenue down 27% and total sales down roughly 12% year over year: QuidelOrtho's third-quarter 2026 revenue miss against Wall Street consensus sent shares down approximately 14% Point-of-Care revenue down 27% and total sales down roughly 12% year over year: QuidelOrtho's third-quarter 2026 revenue miss against Wall Street consensus sent shares down approximately 14%
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into QuidelOrtho Corporation (“QuidelOrtho” or the “Company”) (NasdaqGS: QDEL). According to a securities class action filed against the Company, internal reports and accounts from former employees described serious and unresolved problems with the Company's flagship test, the Savanna Re.
QuidelOrtho's May 2026 quarterly report said China's volume-based procurement program would not likely have a material impact on total annualized revenue. Third-quarter 2026 results showed China revenue down 45%, and QDEL shares fell roughly 14%.
QuidelOrtho narrowed its full-year revenue outlook and announced a restructuring program with its third-quarter 2026 results, and shares fell roughly 14%. QDEL shareholders who lost money have rights, and Levi & Korsinsky is investigating potential securities law violations.
QuidelOrtho Corporation (NASDAQ: QDEL - Get Free Report) has been assigned an average rating of "Reduce" from the six analysts that are presently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation and four have issued a hold recommendation on the company. The average 1 year price objective
QuidelOrtho Corporation ( QDEL ) Q3 2026 Earnings Call November 3, 2026 5:00 PM EST Company Participants Sanjeev Sharma Brian Blaser - President, CEO & Director Micah Young - Chief Financial Officer & Principal Financial Officer Conference Call Participants William Bonello - Craig-Hallum Capital Group LLC, Research Division Tycho Peterson - Jefferies LLC, Research Division Jack Meehan - Operon Research, LLC Casey Woodring - JPMorgan Chase & Co, Research Division Presentation Operator Welcome to the QuidelOrtho Third Quarter 2026 Financial Results Conference Call and webcast. [Operator Instructions] Please note, this conference call is being recorded.